Singapore General Hospital   Report issue

Academic/Hospital Phase 1 Phase 2 Phase 3 Phase 4
Founded: Bukit Merah Singapore (1821)

Organization Overview

First Clinical Trial
2004
NCT00519519
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

Department of Respiratory and Critical Care Medicine, Singapore General Hospital | Department of Surgery, Singapore General Hospital | Kinjal Doshi | National Neuroscience Institute Singapore | National Neuroscience Institute, Singapore General Hospital | National Neuroscience Institute, Singapore General Hospital Campus | Singapore General Hospital

Active Ingredients

Drugs in Phase 4 Trials (20)

acitretin (soriatane) (2 trials)

amoxicillin (1 trial)

clavulanate (Augmentin) (1 trial)

cyclosporine (sandimmune) (2 trials)

ferric carboxymaltose (Injectafer) (1 trial)

fumaric acid esters (1 trial)

interferon alpha-2b (Intron-A) (1 trial)

ixekizumab (taltz) (1 trial)

ketotifen (zaditor) (1 trial)

leflunomide (arava) (1 trial)

methotrexate (2 trials)

methoxyflurane (penthrane) (1 trial)

naltrexone (revia) (1 trial)

pregabalin (lyrica) (1 trial)

rivastigmine (exelon) (1 trial)

secukinumab (cosentyx) (1 trial)

sitagliptin (januvia) (1 trial)

sulfasalazine (azulfidine) (1 trial)

testosterone (delatestryl) (1 trial)

tramadol (Ultram) (1 trial)

Drugs in Phase 3 Trials (24)

11c-metomidate (2 trials)

acetylsalicylic acid (aspirin) (1 trial)

alfuzosin (uroxatral) (1 trial)

amphotericin b (fungizone) (1 trial)

angelica (1 trial)

autologous cd133+ stem cells (1 trial)

ciprofloxacin (cipro) (2 trials)

colchicine (colbenemid) (1 trial)

curcuma longa (1 trial)

doripenem (doribax) (1 trial)

empagliflozin (jardiance) (1 trial)

epinephrine (levophed) (1 trial)

fenofibrate (fenoglide) (1 trial)

hyaluronic acid (1 trial)

levodopa (larodopa) (1 trial)

omeprazole (prilosec) (1 trial)

platelet-rich plasma (2 trials)

polymyxin b sulfate (poly-rx) (1 trial)

siwu tang (1 trial)

sorafenib (nexavar) (2 trials)

sulfamethoxazole (gantanol) (1 trial)

trimethoprim (2 trials)

ty027 (1 trial)

vasopressin (vasostrict) (1 trial)

Drugs in Phase 2 Trials (59)

aldesleukin (Proleukin) (1 trial)

allogeneic cik cells (1 trial)

apalutamide (erleada) (1 trial)

atezolizumab (Tecentriq) (1 trial)

autologous cytokine induced killer cells (1 trial)

benralizumab (fasenra) (1 trial)

bevacizumab (avastin) (1 trial)

bifidobacterium breve (1 trial)

bifidobacterium infantis (1 trial)

bifidobacterium longum (1 trial)

bortezomib (velcade) (3 trials)

caffeine (1 trial)

carboplatin (paraplatin) (2 trials)

carfilzomib (kyprolis) (1 trial)

cd19 car-t cells (1 trial)

chickpea (1 trial)

coriolus versicolor (1 trial)

cyclophosphamide (cytoxan) (1 trial)

dabrafenib (tafinlar) (1 trial)

daptomycin (cubicin) (1 trial)

daratumumab (darzalex) (1 trial)

decitabine (dacogen) (1 trial)

dexamethasone (1 trial)

durvalumab (imfinzi) (2 trials)

etoposide (vepesid) (2 trials)

etoricoxib (Gencox) (1 trial)

fulvic acid (1 trial)

gentamicin (garamycin) (2 trials)

ibrutinib (imbruvica) (2 trials)

ifosfamide (ifex) (2 trials)

inactivated japanese encephalitis vaccine (Ixiaro) (2 trials)

inactivated rabies vaccine (Imovax) (2 trials)

lactobacillus plantarum (1 trial)

lenalidomide (revlimid) (2 trials)

levothyroxine (Synthroid) (1 trial)

live attenuated chimeric japanese encephalitis vaccine (1 trial)

mdl 28574 (2 trials)

mei6570 (1 trial)

mesna (mesnex) (1 trial)

metformin (glucophage) (2 trials)

modipafant (1 trial)

oxytocin (syntocinon) (1 trial)

paclitaxel (taxol) (1 trial)

panobinostat (farydak) (1 trial)

pika rabies vaccine (2 trials)

platelets (1 trial)

rituximab (rituxan) (3 trials)

sargramostim (leukine) (1 trial)

sars-cov-2 specific t cells (1 trial)

Streptococcus thermophilus (1 trial)

syngeneic t lymphocytes (1 trial)

thalidomide (Thalomid) (1 trial)

t lymphocytes (1 trial)

tocotrienol (1 trial)

trametinib (mekinist) (1 trial)

urea (2 trials)

vancomycin (Vancocin) (1 trial)

yellow fever vaccine 17d strain (2 trials)

zoledronic acid (zometa) (1 trial)

Drugs in Phase 1 Trials (7)

autologous serum (1 trial)

autologous umbilical cord blood (1 trial)

azacitidine (vidaza) (1 trial)

ppdpsc18 (1 trial)

pracinostat (1 trial)

ty014 (1 trial)

tyzivumab (1 trial)

Drugs in Other Trials (9)

ceftriaxone (rocephin) (1 trial)

ertapenem (invanz) (1 trial)

fentanyl (Innovar) (1 trial)

glycerin (1 trial)

glycine (1 trial)

lidocaine (xylocaine) (1 trial)

midazolam (versed) (1 trial)

ropivacaine (naropin) (1 trial)

tacrolimus (prograf) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Acute Pain (Phase 4)

Adenoma (Phase 1)

Anemia (Phase 4)

Arthritis (Phase 4)

Arthritis, Rheumatoid (Phase 4)

Aspergillosis (Phase 3)

Bacteremia (Phase 3)

Brain Diseases (Phase 1)

Brain Ischemia (Phase 1)

Breast Neoplasms (Phase 2)

Calculi (Phase 3)

Carcinoma (Phase 3)

Carcinoma, Hepatocellular (Phase 3)

Cognitive Dysfunction (Phase 4)

Communicable Diseases (Phase 2)

Coronavirus Infections (Phase 3)

Dengue (Phase 4)

Diabetes Mellitus (Phase 4)

Diabetes Mellitus, Type 2 (Phase 4)

Diabetic Nephropathies (Phase 3)

Diarrhea (Phase 4)

Digestive System Diseases (Phase 2)

Encephalitis (Phase 2)

Encephalitis, Japanese (Phase 2)

End Stage Liver Disease (Phase 3)

Enteropathy-Associated T-Cell Lymphoma (Phase 2)

Fatty Liver (Phase 2)

Fever (Phase 4)

Gastrointestinal Diseases (Phase 2)

Healthcare-Associated Pneumonia (Phase 3)

Heart Arrest (Phase 3)

Hematologic Neoplasms (Phase 2)

Hemorrhage (Phase 3)

Hepatitis (Phase 4)

Hepatitis A (Phase 4)

Hepatitis B (Phase 4)

Hepatitis B, Chronic (Phase 4)

Hepatitis, Chronic (Phase 4)

Hodgkin Disease (Phase 2)

Hyperaldosteronism (Phase 1)

Hypertension (Phase 1)

Hypoxia (Phase 1)

Hypoxia-Ischemia, Brain (Phase 1)

Immunoblastic Lymphadenopathy (Phase 2)

Infections (Phase 2)

Inflammation (Phase 3)

Insulin Resistance (Phase 4)

Ischemia (Phase 1)

Kidney Diseases (Phase 3)

Leukemia (Phase 2)

Leukemia, Lymphocytic, Chronic, B-Cell (Phase 2)

Leukemia, Myelogenous, Chronic, BCR-ABL Positive (Phase 2)

Leukemia, Myeloid (Phase 2)

Liver Cirrhosis (Phase 3)

Liver Diseases (Phase 3)

Lymphoma (Phase 2)

Lymphoma, B-Cell (Phase 2)

Lymphoma, B-Cell, Marginal Zone (Phase 2)

Lymphoma, Extranodal NK-T-Cell (Phase 2)

Lymphoma, Large B-Cell, Diffuse (Phase 2)

Lymphoma, Large-Cell, Anaplastic (Phase 2)

Lymphoma, T-Cell (Phase 2)

Lymphoma, T-Cell, Peripheral (Phase 2)

Multiple Myeloma (Phase 2)

Myelodysplastic Syndromes (Phase 2)

Neoplasms (Phase 2)

Neoplasms, Plasma Cell (Phase 2)

Non-alcoholic Fatty Liver Disease (Phase 2)

Osteoarthritis (Phase 3)

Osteoarthritis, Knee (Phase 3)

Pain, Postoperative (Phase 2)

Peptic Ulcer (Phase 3)

Peptic Ulcer Hemorrhage (Phase 3)

Peripheral Nervous System Diseases (Phase 2)

Pleural Effusion (Phase 4)

Pneumonia (Phase 3)

Pneumonia, Ventilator-Associated (Phase 3)

Precursor Cell Lymphoblastic Leukemia-Lymphoma (Phase 2)

Preleukemia (Phase 2)

Prostatic Neoplasms (Phase 2)

Psoriasis (Phase 4)

Rabies (Phase 2)

Radiculopathy (Phase 4)

Respiratory Distress Syndrome (Phase 2)

Scleroderma, Diffuse (Phase 2)

Scleroderma, Systemic (Phase 2)

Sclerosis (Phase 2)

Spinal Cord Diseases (Phase 4)

Spondylosis (Phase 4)

Stroke (Phase 3)

Syndrome (Phase 2)

Thyroid Diseases (Phase 2)

Thyroid Neoplasms (Phase 2)

Ulcer (Phase 3)

Urinary Calculi (Phase 3)

Virus Diseases (Phase 2)

Weight Gain (Phase 2)

Xerophthalmia (Phase 1)

Yellow Fever (Phase 2)

Zika Virus Infection (Phase 1)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 86
  • # of Trial APIs: 119